Capital Investment Advisors LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Capital Investment Advisors LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 678,325 shares of the biopharmaceutical company’s stock after buying an additional 5,984 shares during the period. Capital Investment Advisors LLC’s holdings in Pfizer were worth $24,881,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. 25 LLC acquired a new position in Pfizer during the first quarter worth $25,000. Worth Asset Management LLC purchased a new position in shares of Pfizer in the first quarter valued at $29,000. Freedom Wealth Alliance LLC acquired a new position in shares of Pfizer during the 4th quarter worth $35,000. Macroview Investment Management LLC boosted its position in shares of Pfizer by 70.0% in the 1st quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 396 shares in the last quarter. Finally, GeoWealth Management LLC acquired a new stake in Pfizer in the 1st quarter valued at about $49,000. 68.05% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 1.3 %

Shares of NYSE PFE opened at $33.64 on Tuesday. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $189.93 billion, a PE ratio of 8.95, a P/E/G ratio of 1.14 and a beta of 0.59. The firm has a fifty day moving average of $35.80 and a 200-day moving average of $37.96. Pfizer Inc. has a 52-week low of $33.44 and a 52-week high of $54.93.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.57 by $0.10. The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The firm’s revenue was down 54.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.04 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were paid a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, July 27th. This represents a $1.64 annualized dividend and a yield of 4.88%. Pfizer’s dividend payout ratio is currently 43.62%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a report on Monday. Truist Financial reiterated a “buy” rating and set a $62.00 target price on shares of Pfizer in a report on Wednesday, September 13th. HSBC started coverage on Pfizer in a research report on Friday, July 14th. They issued a “buy” rating and a $50.00 price objective on the stock. Barclays dropped their price objective on Pfizer from $40.00 to $38.00 in a research report on Tuesday, July 11th. Finally, StockNews.com assumed coverage on shares of Pfizer in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Twelve investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $46.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.